Burosumab’s efficacy in XLH or FGF23-mediated hypophosphatemia with PHEX PV is well documented; however, its effectiveness in non-XLH FGF23-mediated hypophosphatemia is based on case reports and small studies of TIO. The gene discussed is FGF23; the disease is acquired polycythemia vera.